Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

Core Viewpoint - Taysha Gene Therapies, Inc. is set to report its financial results for Q3 2025 and will host a corporate update conference call on November 4, 2025, at 8:30 AM Eastern Time [1] Company Overview - Taysha Gene Therapies is a clinical-stage biotechnology company focused on AAV-based gene therapies for severe monogenic diseases of the central nervous system [2] - The lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies [2] - The company aims to address severe unmet medical needs and improve the lives of patients and caregivers through transformative medicines [2] - Taysha's management team has proven experience in gene therapy development and commercialization, leveraging this expertise to translate treatments from bench to bedside [2]